Abbott Laboratories has officially completed its landmark $21 billion acquisition of Exact Sciences on March 23, 2026, marking one of the largest healthcare deals in recent history. The transaction, first announced in November 2025, saw Abbott acquire all outstanding shares of Exact Sciences at $105.00 per share in cash, with an enterprise value of approximately $23 billion including the assumption of roughly $1.8 billion in net debt.
The deal was funded through a massive $20 billion senior notes offering that Abbott executed in early March 2026. This significant capital raise underscores the strategic importance Abbott places on expanding its diagnostics portfolio into the high-growth cancer screening segment. The acquisition received all necessary regulatory approvals and shareholder votes in the months leading up to today's closing.
Exact Sciences is widely recognized as an industry leader in noninvasive colorectal cancer screening. Its flagship product, Cologuard, has revolutionized how patients and physicians approach early detection of colorectal cancer by offering a convenient at-home screening alternative. The company also developed Cancerguard, an innovative multi-cancer early detection test that represents the next frontier in preventive oncology diagnostics.
With this acquisition, Abbott is now positioned to lead in the estimated $60 billion global cancer diagnostics market. The combination of Abbott's extensive global distribution network and manufacturing capabilities with Exact Sciences' cutting-edge screening technologies is expected to accelerate the adoption of cancer screening tests worldwide. Industry analysts have praised the strategic fit between the two companies.
From a financial perspective, the deal is expected to add approximately $3 billion in incremental sales during 2026 and accelerate Abbott's overall sales growth by roughly half a percentage point. However, the acquisition will dilute Abbott's 2026 adjusted earnings per share by approximately $0.20 as the company absorbs integration costs and financing expenses associated with the transaction.
Abbott's leadership has emphasized that the acquisition represents a transformative step in the company's long-term strategy to become the preeminent player in cancer diagnostics. The integration of Exact Sciences' research and development capabilities is expected to yield new innovations in early cancer detection, potentially saving millions of lives through earlier intervention and treatment.
Wall Street has responded favorably to the closing of the deal, with Abbott shares trading higher in early sessions. Analysts note that while the near-term earnings dilution is expected, the long-term revenue growth potential from the rapidly expanding cancer diagnostics market far outweighs the short-term financial impact. The acquisition solidifies Abbott's position as one of the most diversified and forward-looking healthcare companies in the world.
Comments